A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

Exclusion Criteria

• •Participants with congenital or acquired hypogonadism for whom long-term therapy with placebo would not be medically appropriate
• •Participants with prostate specific antigen (PSA) \> 3.0 ng/mL (or 1.5 if on 5-alpha reductase inhibitors)
• •Participants who have been treated with testosterone in the past 6 months and for whom testosterone therapy is contraindicated
• •Confirmed testosterone \< 100 ng/dL
• •Body Mass Index (BMI) \> 50
• •Hemoglobin A1c (HbA1C) \> 11%
• •Hematocrit (Hct) \> 50%
• •Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min
• •History of deep vein thrombosis or pulmonary embolism or prostate cancer or heart failure (Class III and IV).